Literature DB >> 2160884

Lisinopril in elderly patients with hypertension. Long term effects on renal and metabolic function.

M S Laher1.   

Abstract

The efficacy and tolerability of lisinopril administered once daily were evaluated in a 12-week open study of 60 elderly patients aged between 65 and 85 years (mean 75 years) with essential hypertension. Mean sitting blood pressure was reduced from 190/106 +/- 6.3/1.3mm Hg (mean +/- SEM) at entry to 162/89 +/- 5.5/0.9 mm Hg after 12 weeks of treatment (p less than 0.001). There was no significant alteration in heart rate, and no occurrence of postural hypotension. The median daily dose of lisinopril was 20mg (range 5 to 40 mg) and only 4 patients required the addition of a diuretic. Mean glomerular filtration rate (GFR) at entry was 61.6 +/- 3.4 ml/min and was unchanged after 12 weeks of therapy. 25 patients continued to receive treatment for 1 year, and 20 of these completed 2 years of treatment. Control of blood pressure was maintained, and heart rate, biochemical parameters and GFR remained unaltered throughout the study. Renal function was preserved and renal blood flow, measured in a group of 14 patients, was significantly increased (p less than 0.025) at the end of the first year after treatment with lisinopril. Thus, in the elderly, lisinopril was well tolerated and highly effective in lowering blood pressure, and renal function was maintained.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160884     DOI: 10.2165/00003495-199000392-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  44 in total

1.  Effects of aging on the kidney.

Authors:  M Epstein
Journal:  Fed Proc       Date:  1979-02

Review 2.  Elderly hypertensive patient. Epidemiologic review.

Authors:  H M Spotnitz
Journal:  N Y State J Med       Date:  1978-06

3.  Changes in renal function in essential hypertension.

Authors:  F C Reubi; P Weidmann; J Hodler; P T Cottier
Journal:  Am J Med       Date:  1978-04       Impact factor: 4.965

4.  Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study.

Authors:  G Muiesan; E Agabiti-Rosei; R Buoninconti; V Cagli; A Carotti; L Corea; P Innocenti; M Malerba; E Paciaroni; A Pirrelli
Journal:  J Hypertens Suppl       Date:  1987-12

5.  Efficacy and safety of lisinopril in older patients with essential hypertension.

Authors:  H J Gomez; S G Smith; F Moncloa
Journal:  Am J Med       Date:  1988-09-23       Impact factor: 4.965

6.  Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy.

Authors:  A P Niarchos; L M Resnick; D L Weinstein; J H Laragh
Journal:  Am J Med       Date:  1985-10       Impact factor: 4.965

7.  Captopril in the treatment of the elderly hypertensive patient.

Authors:  A C Jenkins; J R Knill; G R Dreslinski
Journal:  Arch Intern Med       Date:  1985-11

8.  Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure.

Authors:  P C Gautam; E Vargas; M Lye
Journal:  J Pharm Pharmacol       Date:  1987-11       Impact factor: 3.765

9.  Systemic and renal effects of enalapril and its effects on cardiac mass.

Authors:  F G Dunn; W Oigman; H O Ventura; F H Messerli; I Kobrin; E D Frohlich
Journal:  J Hypertens Suppl       Date:  1984-12

Review 10.  Drug therapy in the elderly.

Authors:  J G Ouslander
Journal:  Ann Intern Med       Date:  1981-12       Impact factor: 25.391

View more
  5 in total

Review 1.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 2.  The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

Authors:  C J Bulpitt; A E Fletcher; A Amery; J Coope; J G Evans; S Lightowlers; K O'Malley; A Palmer; J Potter; P Sever
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 3.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

4.  Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.

Authors:  B Santos Ramos; M J Piña Vera; E Carvajal Gragera; M Atienza Fernández
Journal:  Pharm World Sci       Date:  1993-10-15

Review 5.  ACE inhibitors. Differential use in elderly patients with hypertension.

Authors:  Z H Israili; W D Hall
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.